<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mink Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/mink-therapeutics-inc</link>
<description>Latest news and press releases for Mink Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 19:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mink-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583e878dffbe2df0fce35.webp</url>
<title>Mink Therapeutics Inc</title>
<link>https://6ix.com/company/mink-therapeutics-inc</link>
</image>
<item>
<title>MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-phase-ii-data-on-immune-reprogramming-and-durable-survival-in-pd-1-refractory-gastroesophageal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-phase-ii-data-on-immune-reprogramming-and-durable-survival-in-pd-1-refractory-gastroesophageal-cancer</guid>
<pubDate>Fri, 17 Apr 2026 19:00:00 GMT</pubDate>
<description>First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of patientsInduction strategy linked to improvement in PFS (HR 0.19; p=0,015) and survival rates at 12 and 18 months supported by evidence of immune activation and tumor immune reprogramming NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharma</description>
</item>
<item>
<title>MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-and-memorial-sloan-kettering-to-present-phase-ii-study-of-agent-797-combination-in-pd-1-refractory-gastroesophageal-cancer-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-and-memorial-sloan-kettering-to-present-phase-ii-study-of-agent-797-combination-in-pd-1-refractory-gastroesophageal-cancer-at-aacr-2026</guid>
<pubDate>Fri, 03 Apr 2026 11:30:00 GMT</pubDate>
<description>Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that data</description>
</item>
<item>
<title>MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-to-present-new-data-at-asgct-2026-highlighting-context-dependent-activity-of-inkt-cell-therapy-7</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-to-present-new-data-at-asgct-2026-highlighting-context-dependent-activity-of-inkt-cell-therapy-7</guid>
<pubDate>Thu, 02 Apr 2026 11:30:00 GMT</pubDate>
<description>NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15</description>
</item>
<item>
<title>MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-announces-abstract-acceptance-for-presentation-at-the-american-thoracic-society-ats-2026-international-conference</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-announces-abstract-acceptance-for-presentation-at-the-american-thoracic-society-ats-2026-international-conference</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic</description>
</item>
<item>
<title>MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-q4-and-full-year-2025-results-phase-2-programs-advance-with-impactful-non-dilutive-momentum</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-q4-and-full-year-2025-results-phase-2-programs-advance-with-impactful-non-dilutive-momentum</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in</description>
</item>
<item>
<title>MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-highlight-platform-expansion-across-inkt-cell-therapy-programs</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-highlight-platform-expansion-across-inkt-cell-therapy-programs</guid>
<pubDate>Tue, 17 Mar 2026 11:30:00 GMT</pubDate>
<description>Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potentialNEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter</description>
</item>
<item>
<title>MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-announces-collaboration-with-c-further-to-advance-prame-targeted-inkt-cell-therapy-for-pediatric-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-announces-collaboration-with-c-further-to-advance-prame-targeted-inkt-cell-therapy-for-pediatric-cancers</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for</description>
</item>
<item>
<title>Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/agenus-to-provide-fourth-quarter-and-year-end-2025-financial-report-and-corporate-update-54</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/agenus-to-provide-fourth-quarter-and-year-end-2025-financial-report-and-corporate-update-54</guid>
<pubDate>Wed, 04 Mar 2026 21:30:00 GMT</pubDate>
<description>LEXINGTON, Mass., March 04, 2026--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its fourth quarter and year-end 2025 financial results before the market opens on Monday, March 16, 2026.</description>
</item>
<item>
<title>MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-presents-data-allo-023000422</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-presents-data-allo-023000422</guid>
<pubDate>Wed, 04 Feb 2026 02:30:00 GMT</pubDate>
<description>Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXINGTON, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) today announced that new translational data supporting the role of invariant natural killer T (iNKT) cells in idiopathic pulmonary fibrosis (IPF) were presented at the Eme</description>
</item>
<item>
<title>MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-university-wisconsin-madison-170000383</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-university-wisconsin-madison-170000383</guid>
<pubDate>Thu, 08 Jan 2026 17:00:00 GMT</pubDate>
<description>Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy in patients at risk for GvHD NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (allo-iNKT) cell therapies, today announced the up</description>
</item>
<item>
<title>MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-announces-data-showing-164200414</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-announces-data-showing-164200414</guid>
<pubDate>Thu, 20 Nov 2025 16:42:00 GMT</pubDate>
<description>MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cellsActivates multiple immune pathways to generate potent, lasting anti-tumor activity in lung and MSS colorectal cancer models NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer</description>
</item>
<item>
<title>MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-q3-2025-123000803</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-q3-2025-123000803</guid>
<pubDate>Fri, 14 Nov 2025 12:30:00 GMT</pubDate>
<description>New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive funding from NIH- and philanthropic grantsLaunching Phase 2+ trial in severe pulmonary disease in US population with FDA-validated endpointsAdded national leaders in pulmonary medicine, trauma, and biodefense join MiNK management (Dr. Hammond) and Board (Dr. Holcomb) to drive pivotal developmentCash run</description>
</item>
<item>
<title>MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-durable-responses-140000406</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-durable-responses-140000406</guid>
<pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
<description>Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s potential to restore responsiveness in PD-1–resistant diseaseFavorable safety and reproducible activity reinforce MiNK’s leadership in allogeneic iNKT cell therapy NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-sta</description>
</item>
<item>
<title>MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-report-third-quarter-140700975</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-report-third-quarter-140700975</guid>
<pubDate>Wed, 05 Nov 2025 14:07:00 GMT</pubDate>
<description>NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th. The announcement follows MiNK’s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meetin</description>
</item>
<item>
<title>MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-present-breaking-data-130000526</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-present-breaking-data-130000526</guid>
<pubDate>Thu, 30 Oct 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that late-breaking data demonstrating durable clinical activity of AgenT-797, allo-INKTs, in advanced solid tumors will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 7–9, 2025, in N</description>
</item>
<item>
<title>MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-appoints-colonel-ret-113000850</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-appoints-colonel-ret-113000850</guid>
<pubDate>Mon, 29 Sep 2025 11:30:00 GMT</pubDate>
<description>Strengthening Leadership to Accelerate iNKT Therapies into Immune-Mediated Disease, Pulmonary Disorders, and Global Health Security Colonel (Ret.) John B. Holcomb, MD Colonel (Ret.) John B. Holcomb, MD NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors. Dr. Ho</description>
</item>
<item>
<title>MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-dr-jennifer-buell-113000657</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-dr-jennifer-buell-113000657</guid>
<pubDate>Thu, 25 Sep 2025 11:30:00 GMT</pubDate>
<description>NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced that its President and Chief Executive Officer, Dr. Jennifer Buell, will deliver a featured plenary address at the 10th Annual CAR-TCR Summit, taking place September 23–26, 2025, in Boston, MA. The CAR-TCR Summit is one of the industry’s most influential gatherings of academic, clinical, and bi</description>
</item>
<item>
<title>MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-appoints-dr-terese-113000950</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-appoints-dr-terese-113000950</guid>
<pubDate>Thu, 18 Sep 2025 11:30:00 GMT</pubDate>
<description>Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately. Dr. Hammond is a nationally recog</description>
</item>
<item>
<title>Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/update-agenus-aug-27-stakeholder-webcasttransformative-io-updates-botbal-data-battman-preview-zydus-partnership-momentum-and-mink-spotlight</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/update-agenus-aug-27-stakeholder-webcasttransformative-io-updates-botbal-data-battman-preview-zydus-partnership-momentum-and-mink-spotlight</guid>
<pubDate>Tue, 26 Aug 2025 13:37:00 GMT</pubDate>
<description>LEXINGTON, Mass., August 26, 2025--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET which introduces a new virtual format to provide an engaging experience for attendees, along with an updated participation link.</description>
</item>
<item>
<title>MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results</title>
<link>https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-clinical-strategic-113000168</link>
<guid isPermaLink="true">https://6ix.com/company/mink-therapeutics-inc/news/mink-therapeutics-reports-clinical-strategic-113000168</guid>
<pubDate>Thu, 14 Aug 2025 11:30:00 GMT</pubDate>
<description>Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today annou</description>
</item>
</channel>
</rss>